Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Moore

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Journal of Robotic Surgery|September 18, 2016
Surgical staging of endometrial cancer: robotic versus open technique outcomes in a contemporary single surgeon seriesMeenu Goel, Terrell W Zollinger, David H Moore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistanceSarah Freitas, David H Moore, Helen Michael, et al.
Gynecologic Oncology|December 27, 2005
Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group studyRichard P McQuellon, Howard T Thaler, David Cella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group studyMitchell Morris, John A Blessing, Bradley J Monk, et al.
Gynecologic Oncology|August 7, 2004
An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group studyDavid H Moore, James T Kauderer, Jeffrey Bell, et al.
American Journal of Obstetrics and Gynecology|June 21, 2008
Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studiesSteven C Plaxe, Sandra E Brooks, Chunquiao Tian, et al.
Gynecologic Oncology|October 27, 2009
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group StudyDavid H Moore, Chunqiao Tian, Bradley J Monk, et al.
Gynecologic Oncology|February 15, 2003
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group studyPeter G Rose, John A Blessing, Harrison G Ball, et al.
Obstetrics and Gynecology|August 25, 2010
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek, Eva Chalas, Mitchell Edelson, et al.
Gynecologic Oncology|July 4, 2006
Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group studySteven E Waggoner, Kathleen M Darcy, Barbara Fuhrman, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Robotic Surgery|September 18, 2016
Surgical staging of endometrial cancer: robotic versus open technique outcomes in a contemporary single surgeon seriesMeenu Goel, Terrell W Zollinger, David H Moore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistanceSarah Freitas, David H Moore, Helen Michael, et al.
Gynecologic Oncology|December 27, 2005
Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group studyRichard P McQuellon, Howard T Thaler, David Cella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group studyMitchell Morris, John A Blessing, Bradley J Monk, et al.
Gynecologic Oncology|August 7, 2004
An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group studyDavid H Moore, James T Kauderer, Jeffrey Bell, et al.
American Journal of Obstetrics and Gynecology|June 21, 2008
Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studiesSteven C Plaxe, Sandra E Brooks, Chunquiao Tian, et al.
Gynecologic Oncology|October 27, 2009
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group StudyDavid H Moore, Chunqiao Tian, Bradley J Monk, et al.
Gynecologic Oncology|February 15, 2003
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group studyPeter G Rose, John A Blessing, Harrison G Ball, et al.
Obstetrics and Gynecology|August 25, 2010
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek, Eva Chalas, Mitchell Edelson, et al.
Gynecologic Oncology|July 4, 2006
Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group studySteven E Waggoner, Kathleen M Darcy, Barbara Fuhrman, et al.
Pageof 4